Hence, RHB is maintaining its “neutral” recommendation on Singapore’s healthcare sector.
SINGAPORE (Dec 20): Singapore’s healthcare sector is expected to face strong pricing competition from neighbouring countries, such as Malaysia and Thailand where patients are able to also receive quality medical treatment at a faction of the cost as compared to Singapore due to the much lower treatment, drug and room costs.
Furthermore, the SGD’s strength compared to the other key regional countries adds to the pressure on costs, weakening Singapore’s appeal to medical tourists.
